Pfizer Inc vs Redwire Corporation — how do they compare? Pfizer Inc trades at $27.91 (market cap $158.39B), while Redwire Corporation trades at $10.76 (market cap $2.81B). The key difference: Pfizer Inc is far larger — about 56.4× Redwire Corporation's market cap, and Pfizer Inc pays a 6.19% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| PFE | RDW | |
|---|---|---|
Market Cap | $158.39B | $2.81B |
Volume | 29,869,932 | — |
Sector | Health | Technology |
52-Week High | $29.02 | $25.90 |
52-Week Low | $23.60 | $5.06 |
Enterprise Value | $209.89B | $2.34B |
Dividend Yield | 6.19% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Redwire Corporation (RDW) trades at $11.23, up 6.65% today, with a bullish technical signal and strong analyst support. The stock shows improving revenue trends with 2026 projections reaching $426 million, though profitability remains challenged with negative margins. Recent news highlights strategic investments in phased-array technology and record backlog growth, while institutional interest is strong with BlackRock's $196.5 million position.
The outlook remains cautiously optimistic given 80% analyst buy ratings and a $12.17 price target, but significant risks persist including continued cash burn, execution challenges, and premium valuation. Investors face the tension between promising space/defense growth opportunities and the company's ongoing inability to achieve profitability despite revenue expansion.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →